Prognostic impact of post-chemoradiotherapy muscle quality in non-elderly adults with esophageal squamous cell carcinoma
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.123400 ↗Abstract
BACKGROUND Definitive chemoradiotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC); however, marked prognostic heterogeneity exists and simple predictive biomarkers are lacking. Although skeletal muscle density (SMD) reflects muscle quality, its posttreatment prognostic value and age-dependent modifying effect in ESCC remain unclear. AIM To explore the prognostic significance of post-treatment SMD (post-SMD) and to clarify the age-related interaction in patients with ESCC undergoing definitive chemoradiotherapy. METHODS Altogether, 255 eligible ESCC patients were retrospectively enrolled. Post-SMD was calculated using L3 vertebral-level abdominal computed tomography images. Additionally, multivariate logistic regression and restricted cubic spline were utilized to analyze the influencing factors and nonlinear age-post-SMD correlation. Moreover, survival analyses and Cox regression were performed to assess the prognostic value, followed by the construction and validation of an age-subgroup prognostic model. RESULTS In the entire cohort, lower post-SMD was significantly associated with worse survival (P = 0.034). A nonlinear relationship was identified between age and post-SMD, with 64 years established as the inflection point (P = 0.016). Consequently, the prognostic impact of post-SMD was highly age-dependent. It served as a significant predictor of poor survival exclusively in patients aged < 64 years (P = 0.020) but not in those ≥ 64 years (P = 0.439). Multivariate analysis confirmed that higher post-SMD was an independent protective factor for survival (hazard ratio = 0.633, P = 0.006). Based on these findings, we developed a prognostic model incorporating post-SMD specifically for patients under 64 years. This model demonstrated excellent performance in distinguishing high-risk patients (P < 0.001), exhibiting high discriminatory power [12-month area under the curve (AUC) = 0.820; 36-month AUC = 0.867], good calibration, and providing a positive net clinical benefit in decision curve analysis. CONCLUSION In this study cohort, post-SMD is a vital prognostic biomarker, and age acts as a core effect modifier in evaluating its prognostic significance. This finding can provide references for precise risk stratification and individualized management of the corresponding population.
EUVIMED